Mesoblast Limited

BioTech/Drugs - New York, NY, US

Mesoblast Limited Details

Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs.The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are:• RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD)• Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection• REVASCOR® for advanced chronic heart failure, and• MPC-06-ID for chronic low back pain due to degenerative disc disease.The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020.The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.Mesoblast's approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.

Mesoblast Limited logo, Mesoblast Limited contact details
Website: mesoblast.com
Employees: 100 - 249
HQ: 212-880-2060
Location: New York, NY, US
Revenue: 10 - 20 Million
Cell-based therapies cellular medicines Mesenchymal Lineage Adult Stem Cells regenerative medicine Biotech
Mesoblast Limited Technologies
Email Providers

Outlook

Domain Name Services

Cloudflare DNS

CMS

Drupal

Other

Microsoft Office 365

Hosting

CloudFlare Hosting

View All Technologies Used At Mesoblast Limited

Contacting Mesoblast Limited: Connect with Executives and Employees

Get in Touch with Mesoblast Limited Executives and Employees

Connecting with Mesoblast Limited's Executives and Workforce

Accessing Contact Information for Mesoblast Limited Executives

Connecting with Mesoblast Limited: Reach Out to Their Team

Discover How to Contact Mesoblast Limited Executives and Staff

Looking to connect with Mesoblast Limited executives or employees?

Seeking to Get in Touch with Mesoblast Limited Executives or Staff?

Want to Reach Out to Mesoblast Limited Executives or Team Members?

In Search of Contact Details for Mesoblast Limited Professionals?

Connecting with Mesoblast Limited: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z